Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | GLA | P06280 | 3/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.52 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29685650 | 1.00 | ALDH1A1 (0.54) | ALDH1A1GLANR4A1NR4A2NR4A3 | |
| SCHEMBL1987428 | 0.87 | MAOA (0.62) | ALDH1A1GLATBK1MAOATTR | |
| SCHEMBL2695633 | 0.86 | ALDH1A1 (0.49) | ALDH1A1GLANR4A1NR4A2NR4A3 | |
| SCHEMBL27697686 | 0.84 | MAOA (0.58) | ALDH1A1GLATBK1MAOATTR | |
| SCHEMBL22645255 | 0.84 | MAPT (0.53) | ALDH1A1GLAMAOATTRMAPT | |
| SCHEMBL30476189 | 0.83 | ALDH1A1 (0.76) | ALDH1A1GLATBK1MAOAKDM4E | |
| SCHEMBL2012858 | 0.83 | ALDH1A1 (0.76) | ALDH1A1GLATBK1MAOAKDM4E | |
| SCHEMBL11401526 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GLAMAOAKDM4EMAOB | |
| SCHEMBL4586087 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GLATBK1MAOAALOX15 | |
| Silver SCHEMBL11471729 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GLATBK1MAOATTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518109-A | Organic compound, application thereof and organic electroluminescent device | 北京绿人科技有限责任公司 | 2020-08-11 | — | — | CN | claimed |
| CN-110540552-A | Aromatic phosphorus oxide compound and preparation method of aromatic phosphorus oxide medicine thereof | UNIV HUNAN | 2019-12-06 | — | — | CN | claimed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | claimed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | claimed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | claimed |
| EP-0891354-B1 | N-AMINOALKYLDIBENZOFURANCARBOXAMIDES AS DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2001-09-12 | — | — | EP | claimed |
| CN-119264185-A | Synthesis method of dibenzofuran group-based blue light hole blocking material | 棓诺(苏州)新材料有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-3061759-B1 | NITRILE SUBSTITUTED DIBENZOFURANS | IDEMITSU KOSAN CO (JP) | 2019-12-25 | — | — | EP | disclosed |
| CN-110540552-A | Aromatic phosphorus oxide compound and preparation method of aromatic phosphorus oxide medicine thereof | UNIV HUNAN | 2019-12-06 | — | — | CN | disclosed |
| US-9991449-B2 | Anthracene derivatives for organic light-emitting diode and organic light-emitting diode including the same | SFC CO., LTD. (KR) | 2018-06-05 | — | — | US | disclosed |
| US-9991449-B2 | Anthracene derivatives for organic light-emitting diode and organic light-emitting diode including the same | SFC CO., LTD. (KR) | 2018-06-05 | — | — | US | disclosed |
| EP-3072943-B1 | DIBENZOFURAN/CARBAZOLE-SUBSTITUTED BENZONITRILES | IDEMITSU KOSAN CO (JP) | 2018-05-02 | — | — | EP | disclosed |
| WO-2003065989-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2000056691-A1 | SYNTHESIS OF VAPOL LIGANDS | ARCH DEVELOPMENT CORPORATION (US) | 2000-09-28 | — | — | WO | disclosed |
| US-4729839-A | THIO ESTER-ETHERS, ESTERIFICATION, ETHERIFICATION | PHILLIPS PETROLEUM COMPANY (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0249783-A1 | Water soluble lubricating additives | PHILLIPS PETROLEUM COMPANY (US) | 1987-12-23 | — | — | EP | disclosed |
| US-4615836-A | REACTING ALKYL, MERCAPTOALKANOL WITH CARBOXYLIC ACID; TITANIUM-CONTAINING CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1986-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | ALDH1A1 642/4885GLA 209/4885NR4A1 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.